Key facts
- It has raised $12.7M; the latest was Seed Round ($12.7M) in Jun 2025.
- Notable investors include Bpifrance, Kurma Partners, SambrInvest, Capital Grand Est, Angelini Ventures — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Elkedonia
- ·The full record, as it builds
Funding rounds
No funding rounds for Elkedonia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Elkedonia
Operator of an antidepressant treatment development firm intended to transform the treatment of mental health disorders. The company specializes in developing a safe, well-tolerated, and effective antidepressant therapy for depression, advancing psychiatric treatments and developing a neuroplastogen, enabling patients to rediscover the pleasures of life and significantly reduce the risks of suicide and relapse.
- Sector
- Healthcare
- HQ
- STRASBOURG, France
- Founded
- 2025
- Employees
- 2
- Website
- elkedonia.com/
- Ownership
- Privately Held (backing)
Elkedonia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Elkedonia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Elkedonia in its N-PORT filings yet. We sweep new filings monthly.